Background: Ovarian cancer is the most common fatal malignancy of the gynecology tract. The purpose of this study was to compare serum levels of tumor markers cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in both healthy groups and patients with ovarian cancer. Materials and Methods: this case–control study was performed on Seyed Al-Shohada Hospital in Isfahan. Research on the treatment of 44 patients with ovarian cancer and 44 healthy controls was performed. CA125 and HE4 were measured in serum by sandwich ELISA method. Results: Average CA125 in ovarian cancer patients (83.30 ± 43.99 μ/ml) was significantly higher than in healthy controls (12.39 ± 5.50 μ/ml) (P < 0.001). Average HE4 in ovarian cancer patients (295.41 ± 13...
BACKGROUND: Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secre...
Human epididymis protein 4 (HE4) is a new biomarker for the detection of ovarian cancer. We evaluate...
The National Institute for Health and Clinical Excellence (NICE) guidelines have sparked hot debate ...
Background: Ovarian cancer remains a leading cause of death from gynecological malignancy. Early dia...
Background Human epididymis protein 4 (HE4) measurements in serum have been proposed for improving t...
AIM: Although CA125 is the most widely used cancer marker in the diagnostic approach of pelvic masse...
Fawen Chen,1,2 Jing Shen,3 Jianwei Wang,1 Pengwei Cai,1 Yi Huang3 1Department of Clinical Laboratory...
Background: The addition of human epididymis protein 4 (HE4) to carbohydrate antigen 125 (CA125) in ...
Objective: To evaluate the role of the novel tumor marker human epididymal secretory protein E4 (HE4...
Objective: Evaluating the presence of possible malignant disease in women with ovarian masses relies...
Zhijun Yang,* Chunyin Wei,* Zhaoqing Luo, Li Li Department of Gynecologic Oncology, Guangxi Medical ...
Abstract Background: This study was designed to explore the levels of serum moleculartumor marker...
Introduction: The use of Human Epididymis Protein 4 (HE4) as a biomarker for ovarian cancer is gaini...
Introduction: The use of Human Epididymis Protein 4 (HE4) as a biomarker for ovarian cancer is gaini...
Objective: The aim of the study was to assess the usefulness of various tumor markers (CA125, HE4, b...
BACKGROUND: Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secre...
Human epididymis protein 4 (HE4) is a new biomarker for the detection of ovarian cancer. We evaluate...
The National Institute for Health and Clinical Excellence (NICE) guidelines have sparked hot debate ...
Background: Ovarian cancer remains a leading cause of death from gynecological malignancy. Early dia...
Background Human epididymis protein 4 (HE4) measurements in serum have been proposed for improving t...
AIM: Although CA125 is the most widely used cancer marker in the diagnostic approach of pelvic masse...
Fawen Chen,1,2 Jing Shen,3 Jianwei Wang,1 Pengwei Cai,1 Yi Huang3 1Department of Clinical Laboratory...
Background: The addition of human epididymis protein 4 (HE4) to carbohydrate antigen 125 (CA125) in ...
Objective: To evaluate the role of the novel tumor marker human epididymal secretory protein E4 (HE4...
Objective: Evaluating the presence of possible malignant disease in women with ovarian masses relies...
Zhijun Yang,* Chunyin Wei,* Zhaoqing Luo, Li Li Department of Gynecologic Oncology, Guangxi Medical ...
Abstract Background: This study was designed to explore the levels of serum moleculartumor marker...
Introduction: The use of Human Epididymis Protein 4 (HE4) as a biomarker for ovarian cancer is gaini...
Introduction: The use of Human Epididymis Protein 4 (HE4) as a biomarker for ovarian cancer is gaini...
Objective: The aim of the study was to assess the usefulness of various tumor markers (CA125, HE4, b...
BACKGROUND: Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secre...
Human epididymis protein 4 (HE4) is a new biomarker for the detection of ovarian cancer. We evaluate...
The National Institute for Health and Clinical Excellence (NICE) guidelines have sparked hot debate ...